NEW YORK, Dec. 28, 2016 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC is
investigating potential claims on behalf of purchasers of Amphastar
Pharmaceuticals, Inc. ("Amphastar" or the "Company") (NASDAQ:
AMPH). Such investors are advised to obtain additional information
and assist the investigation by visiting the firm's site:
www.bgandg.com/amph.
The investigation concerns whether Amphastar and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On December 27, 2016, Amphastar
revealed that Armstrong Pharmaceuticals, Inc. ("Armstrong"), its
wholly-owned subsidiary, was issued a complete response letter from
the U.S. Food and Drug Administration ("FDA"), stating that
Armstrong's New Drug Application for Primatene Mist, an epinephrine
inhalation aerosol product, will not be approved in its present
form. The FDA specified that Armstrong needs to change the
product's label and packaging and it should conduct another Human
Factor validation study to assess consumers' ability to use the
product without the guidance of a doctor or pharmacist.
Following this news, Amphastar stock dropped $1.86 per share, or 9.1%, to close at
$18.57 on December 27, 2016.
If you are aware of any facts relating to this investigation, or
purchased Amphastar shares, you can assist this investigation by
visiting the firm's site: www.bgandg.com/amph. You can also contact
Peretz Bronstein or his Investor
Relations Analyst, Yael Hurwitz of
Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-amphastar-pharmaceuticals-inc-amph-300383746.html
SOURCE Bronstein, Gewirtz & Grossman, LLC